Adam Feuerstein on Muck Rack

Adam Feuerstein Verified

As seen in:  The Street

Sr. Columnist at TheStreet, aka the Col. Jessup of biotech/drug stocks. Data Are. I curse. Said one analyst: The likes of Adam Feuerstein attack viciously.

Biotech Stock Mailbag: Receptos, Celldex Therapeutics, Exact Sciences

thestreet.com — BOSTON ( TheStreet) -- This week's Biotech Stock Mailbag discusses three stocks that I like: Receptos , Celldex Therapeutics and That's never happened before. Call it a Brief Era of Good Feeling. @adamfeuerstein is $RCPT drug just another "me too" drug to Novartis' Gilenya?

PTC Therapeutics for Sale? Only to a Foolish, Risk-Blind Buyer

thestreet.com — NEW YORK ( TheStreet) -- I'm throwing cold water on media reports claiming pharmaceutical companies are eyeing PTC Therapeutics for an acquisition. PTC Therapeutics is exploring a possible sale following the receipt of takeover interest from Shire , BioMarin Pharmaceuticals and Vertex Pharmaceuticals , Reuters reported earlier this week, citing "people familiar with the matter."

Ampio Too Busy to Tell Investors Results of Eye Drug Study

thestreet.com — Ampio Pharmaceuticals completed a clinical trial of its diabetic macular edema drug Optina in November, but it is just too busy to disclose results. I'm not kidding.

What to Expect from Vertex Pharma, Next Cystic Fibrosis Drug Results

thestreet.com — BOSTON ( TheStreet) -- Later this quarter, Vertex Pharmaceuticals is expected to disclose new clinical data on its next cystic fibrosis drug, VX-661. The announcement is important because VX-661 is expected to be an essential component of future combination therapies which Vertex hopes will benefit a large population of difficult-to-treat cystic fibrosis patients.

Obesity Drugs: Orexigen Gains Market Share at Expense of Arena, Vivus

thestreet.com — ((( Here's a chart depicting the most current obesity drug market share. The trend is undeniable: Orexigen Therapeutics OREX - Get Report) is gaining, ARNA - Get Report) and VVUS - Get Report) are falling. Arena Pharma Vivus Source: IMS Health via J.P. Morgan.

Activist Hedge Fund Seeks Firing of Ariad Pharma CEO Berger

thestreet.com — NEW YORK (TheStreet) -- Activist hedge fund Sarissa Capital is starting a proxy fight to force the ouster of Ariad Pharmaceuticals founder and CEO Harvey Berger. Sarissa, led by former Carl Icahn lieutenant Alex Denner, is Ariad's largest shareholder with a 6.9% stake in the biotech company.

Biotech Stock Mailbag: MannKind, Mast Therapeutics, Bluebird

thestreet.com — BOSTON ( TheStreet) -- Welcome back to another Biotech Stock Mailbag. @adamfeuerstein I am asking for your reasonable guess on what you consider a success in terms of up-take curve in first 8 weeks.

Article Page | TheStreet

thestreet.mobi — By Adam Feuerstein - 02/18/14 - 1:53 PM EST Tickers in this article: PRAN Prana Biotechnology had one goal Tuesday: Mine deep into the phase II study of its Huntington's disease drug PBT2 to find anything positive to report.

Achillion: Hep C Drug Discounting May Hurt Our Market Value, Stock Price

thestreet.com — NEW YORK ( TheStreet) -- Achillion Pharmaceuticals announced a 10 million-share stock offering Tuesday night. More on the motivation behind the new financing below, but first, it's worth noting that Achillion added new, cautionary language about hepatitis C drug discounts and reimbursement to the risk section of its updated SEC filings.

Regulus' Dream of a Single-Shot Hepatitis C Cure Falls Short

thestreet.com — LA JOLLA, Calif. ( TheStreet) -- Regulus Therapeutics' dream of developing an ultra-convenient, single-shot cure for hepatitis C took a step backward Monday. Whether Regulus can still succeed with a multi-shot regimen or a combination requiring a shot and daily pills will depend on results from studies not yet conducted.
More Articles →
Feb 27, 2015

RT @SmallBizOnHill: Only Democrats can save the House's 3-week DHS funding bill now -- 43 Republicans so far have voted against it.

Feb 27, 2015

$CVM says Belarus is the "21th" country to allow enrollment in Multikine trial. Goodth toth knowth. Thanksth forth tellingth usth.

Feb 27, 2015

RT @ArchivesBoston: In memory of Leonard Nimoy, one of our favorite records - the listing for the business he started at 17 ow.ly/i/8Ow1N @universalhub

Feb 27, 2015

RT @AndyBiotech: LOL, so $IMV.TO & $GILD #Ebola deal not true? Immunovaccine Disclaims Hoax Press Release marketwired.com/press-release/…

Learn how to connect with Adam on social media by joining Muck Rack Pro



Are You a Journalist?

Make a Portfolio

Create a free Muck Rack account to customize your profile and upload a portfolio of your best work.


Share This Profile